Immunic Names Erik Lundgren Chief Executive Officer

May 27, 2026 — 06:51 am EDT

Written by RTTNews.com for RTTNews

(RTTNews) - Immunic, Inc. (IMUX), a late-stage biotechnology company, on Wednesday said it has appointed Erik Lundgren as its new chief executive officer, effective May 22, 2026, with employment set to begin on June 1.

Lundgren succeeds Daniel Vitt, who will continue to oversee scientific strategy and portfolio advancement while remaining a member of Immunic's board of directors.

Lundgren has nearly 20 years of experience in the biopharmaceutical industry, including commercial strategy, global portfolio leadership and product launches, with a strong background in multiple sclerosis. He previously served as senior vice president of the Commercial Portfolio Organization at Genentech, part of the Roche Group

"As we look to our next phase of growth, including the pivotal phase 3 RMS data readout expected by year-end, preparations for NDA filing in this indication and potential commercialization thereafter, Erik's experience will be invaluable," said Michael W. Bonney, Chair of Immunic's Board of Directors.

RTTNews

Founded in the late 1990s by Andrew Mariathasan in New York, with the goal of covering Wall Street for a new generation of investors, RTTNews has expanded steadily over the years to become a trusted provider of content for a wide array of subjects across several platforms. RTT's Financial Newswire is relied upon by some of the world's largest financial institutions, including banks, brokerages, trading platforms and financial exchanges.

Immunic Names Erik Lundgren Chief Executive Officer

Tags

Latest Articles